Table 1 Main epidemiological features as well as clinical, echocardiographic, and blood samples variables assessed at inclusion in the study group (n = 21 cats with congestive heart failure treated with torasemide) as compared with a contemporary control group of 54 cats with congestive heart failure receiving furosemide as sole loop diuretic treatment
Population of 21 cats treated with torasemide | Control Group (n = 54) | |||||
|---|---|---|---|---|---|---|
n | Median (1st quartile - 3rd quartile) | Minimum - Maximum | n | Median (1st quartile – 3rd quartile) | Minimum - Maximum | |
Epidemiological features | ||||||
Age (years) | 21 | 10.6 (6.5–11.2) | 1.8–15.4 | 54 | 7.2 (5.6–9.8) | 0.9–18.2 |
Weight (kg) | 21 | 4.8 (3.7–6.6) | 3.2–7.0 | 54 | 5.3 (4.5–6.3) | 3.3–7.3 |
Sex (M/F; %) | 16/5; 76/24 | – | – | 33/21 | – | |
Clinical data | ||||||
Heart Murmur (yes/no; %) | 9/12; 43/57 | – | – | 26/28; 48/52 | – | – |
Gallop sound (yes/no; %) | 9/12; 43/57 | – | – | 7/47; 13/87 | – | – |
Arrhythmia (yes/no, %) | 5/16; 24/76 | – | – | 0/54; 0/100 | – | – |
Minimal heart rate | 21 | 225 (192–245) | 170–280 | 54 | 200 (177–230) | 120–320 |
Pre-treatment | ||||||
Furosemide (yes/no; %) | 11/10; 52/48 | – | – | 37/17; 69/31 | – | – |
Benazepril (yes/no; %) | 7/14; 33/67 | – | – | 15/39; 28/72 | – | – |
Clopidogrel (yes/no; %) | 5/16; 24/76 | – | – | 16/38; 30/70 | – | – |
Spironolactone (yes/no %) | 3/18; 14/86 | – | – | 2/52; 4/96 | – | – |
Pimobendan (yes/no; %) | 3/18; 14/86 | – | – | 3/51; 6/94 | – | – |
Taurine (yes/no; %) | 2/19; 10/90 | – | – | 2/52; 4/96 | – | – |
Amlodipine (yes/no; %) | 1/20; 5/95 | – | – | 0/54; 0/100 | – | – |
Diltiazem (yes/no; %) | 1/20; 5/95 | – | – | 0/54; 0/100 | – | – |
Atenolol (yes/no; %) | 0/21; 0/100 | - | - | 1/53; 2/98 | - | - |
Echocardiography | ||||||
Pleural effusion identified (yes/no; %) | 16/5; 76/24 | – | – | 24/30 | – | – |
LA:Ao ratio at end-diastole | 21 | 1.99 (1.82–2.25) | 1.28–3.50 | 54 | 1.88 (1.61–2.10) | 1.30–2.70 |
LA dilation (yes/no; %) | 21/0;100/0 | – | – | 54/0; 100/0 | – | – |
RA (mm) | 21 | 14 (12–20) | 9.7–21.1 | 54 | 14.0 (11.5–15.5) | 6.4–24.8 |
RA dilation (yes/no; %) | 10/11; 48/52 | – | – | 17/37; 31/69 | – | – |
FS (%) | 21 | 42 (31–49) | 22–69 | 54 | 41 (36–49) | 15–75 |
Blood sample | ||||||
Urea (g/L) | 18 | 0.67 (0.56–0.76) | 0.44–1.19 | 45 | 0.67 (0.56–0.82) | 0.40–1.99 |
Creatinine (mg/L) | 18 | 15.4 (12.2–17.4) | 9.0–27.0 | 47 | 14.1 (10.7–20.7) | 5.0–38.0 |
Potassium (mmol/L) | 13 | 3.7 (3.5–4.4) | 3.0–5.3 | 41 | 4.0 (3.4–4.6) | 2.6–5.3 |
Sodium (mmol/L) | 13 | 151 (150–157) | 143.0–163.0 | 36 | 152 (147–157) | 137–174 |
IRIS Stage (n; stages 1/2/3; %) | 18; 10/8/0; 56/44/0 | – | – | 47; 27/18/2; 57/38/4 | – | – |